Turkey’s Competition Board announced on Friday, January 22, it imposed fines on Turkish units of pharmaceutical companies Novartis and Roche for trying to popularize a more expensive medicine used for eye diseases at the expense of a cheaper one.
Novartis was fined 165.46 million lira (US$22.35 million), while Roche was fined 112.97 million lira (US$15.22 million), the board stated.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
